Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049066404> ?p ?o ?g. }
- W2049066404 endingPage "2687" @default.
- W2049066404 startingPage "2677" @default.
- W2049066404 abstract "Study objectives Cardiac surgery with cardiopulmonary bypass (CPB) results in perioperative organ damage caused by the systemic inflammatory response syndrome (SIRS) and ischemia/reperfusion injury. Administration of corticosteroids before CPB has been demonstrated to inhibit the activation of the systemic inflammatory response. However, the clinical benefits of corticosteroid therapy are controversial. This study was designed to document the effects of dexamethasone on cytokine release and perioperative myocardial, pulmonary, renal, intestinal, and hepatic damage, as assessed by specific and sensitive biomarkers. Design and patients A prospective, double-blind, placebo-controlled, randomized trial for dexamethasone was conducted in 20 patients receiving either dexamethasone (1 mg/kg before anesthesia induction and 0.5 mg/kg after 8 h; n = 10) or placebo (n = 10). Different markers were used to assess the SIRS: interleukin (IL)-6, IL-8, IL-10, C-reactive protein (CRP), and tryptase; and organ damage: heart (plasma heart-type fatty acid binding protein, cardiac troponin I [cTnI], creatine kinase-MB), kidneys (N-acetyl-glucosaminidase [NAG], microalbuminuria), intestine (intestinal-type fatty acid binding protein [I-FABP]/liver-type fatty acid binding protein [L-FABP]), and liver (α-glutathione S-transferase). Results Dexamethasone modulated the SIRS with lower proinflammatory (IL-6, IL-8) and higher antiinflammatory (IL-10) IL levels. CRP and tryptase were lower in the dexamethasone group. cTnI values were lower in the dexamethasone group at 6 h in the ICU (p = 0.009). Patients in the dexamethasone group had a longer time to tracheal extubation (18.86 ± 1.13 h vs 15.01 ± 0.99 h, p = 0.02 [mean ± SEM]), with a lower oxygenation index at that time: Pao2/fraction of inspired oxygen ratio, 37.17 ± 1.8 kPa vs 29.95 ± 2.1 kPa (p = 0.009). The postoperative glucose level (10.7 ± 0.6 mmol/L vs 7.4 ± 0.5 mmol/L, p = 0.005) was higher in the dexamethasone group. Serum glucose was independently associated with intestinal injury (urine I-FABP peak, R2 = 42.5%, β = 114.4 ± 31.4, significant at p = 0.002; urine L-FABP peak, R2 = 47.3%, β = 7,714.1 ± 1,920.9, significant at p = 0.001) and renal injury (urine NAG, R2 = 32.1%, β = 0.21 ± 0.07, significant at p = 0.009). Tryptase peaks correlated negatively with peaks of intestinal and renal injury biomarkers. Conclusion Even while inhibiting SIRS, dexamethasone treatment offered no protection against transient, subclinical, perioperative abdominal organ damage. Tryptase release could have a preconditioning effect, offering protection against perioperative intestinal and renal damage. Dexamethasone treatment resulted in more pronounced postoperative pulmonary dysfunction, prolonged time to tracheal extubation, and initiated postoperative hyperglycemia in patients undergoing elective on-pump coronary artery bypass graft surgery. Cardiac surgery with cardiopulmonary bypass (CPB) results in perioperative organ damage caused by the systemic inflammatory response syndrome (SIRS) and ischemia/reperfusion injury. Administration of corticosteroids before CPB has been demonstrated to inhibit the activation of the systemic inflammatory response. However, the clinical benefits of corticosteroid therapy are controversial. This study was designed to document the effects of dexamethasone on cytokine release and perioperative myocardial, pulmonary, renal, intestinal, and hepatic damage, as assessed by specific and sensitive biomarkers. A prospective, double-blind, placebo-controlled, randomized trial for dexamethasone was conducted in 20 patients receiving either dexamethasone (1 mg/kg before anesthesia induction and 0.5 mg/kg after 8 h; n = 10) or placebo (n = 10). Different markers were used to assess the SIRS: interleukin (IL)-6, IL-8, IL-10, C-reactive protein (CRP), and tryptase; and organ damage: heart (plasma heart-type fatty acid binding protein, cardiac troponin I [cTnI], creatine kinase-MB), kidneys (N-acetyl-glucosaminidase [NAG], microalbuminuria), intestine (intestinal-type fatty acid binding protein [I-FABP]/liver-type fatty acid binding protein [L-FABP]), and liver (α-glutathione S-transferase). Dexamethasone modulated the SIRS with lower proinflammatory (IL-6, IL-8) and higher antiinflammatory (IL-10) IL levels. CRP and tryptase were lower in the dexamethasone group. cTnI values were lower in the dexamethasone group at 6 h in the ICU (p = 0.009). Patients in the dexamethasone group had a longer time to tracheal extubation (18.86 ± 1.13 h vs 15.01 ± 0.99 h, p = 0.02 [mean ± SEM]), with a lower oxygenation index at that time: Pao2/fraction of inspired oxygen ratio, 37.17 ± 1.8 kPa vs 29.95 ± 2.1 kPa (p = 0.009). The postoperative glucose level (10.7 ± 0.6 mmol/L vs 7.4 ± 0.5 mmol/L, p = 0.005) was higher in the dexamethasone group. Serum glucose was independently associated with intestinal injury (urine I-FABP peak, R2 = 42.5%, β = 114.4 ± 31.4, significant at p = 0.002; urine L-FABP peak, R2 = 47.3%, β = 7,714.1 ± 1,920.9, significant at p = 0.001) and renal injury (urine NAG, R2 = 32.1%, β = 0.21 ± 0.07, significant at p = 0.009). Tryptase peaks correlated negatively with peaks of intestinal and renal injury biomarkers. Even while inhibiting SIRS, dexamethasone treatment offered no protection against transient, subclinical, perioperative abdominal organ damage. Tryptase release could have a preconditioning effect, offering protection against perioperative intestinal and renal damage. Dexamethasone treatment resulted in more pronounced postoperative pulmonary dysfunction, prolonged time to tracheal extubation, and initiated postoperative hyperglycemia in patients undergoing elective on-pump coronary artery bypass graft surgery." @default.
- W2049066404 created "2016-06-24" @default.
- W2049066404 creator A5013438849 @default.
- W2049066404 creator A5015208849 @default.
- W2049066404 creator A5024108500 @default.
- W2049066404 creator A5026041374 @default.
- W2049066404 creator A5030738510 @default.
- W2049066404 creator A5039836204 @default.
- W2049066404 creator A5085079099 @default.
- W2049066404 date "2005-10-01" @default.
- W2049066404 modified "2023-09-23" @default.
- W2049066404 title "Dexamethasone: Benefit and Prejudice for Patients Undergoing On-Pump Coronary Artery Bypass Grafting" @default.
- W2049066404 cites W114915763 @default.
- W2049066404 cites W1583931582 @default.
- W2049066404 cites W1604174888 @default.
- W2049066404 cites W172055096 @default.
- W2049066404 cites W1871640811 @default.
- W2049066404 cites W1963777860 @default.
- W2049066404 cites W1966524674 @default.
- W2049066404 cites W1969412058 @default.
- W2049066404 cites W1973651409 @default.
- W2049066404 cites W1980235836 @default.
- W2049066404 cites W1980717583 @default.
- W2049066404 cites W1988447687 @default.
- W2049066404 cites W1992719447 @default.
- W2049066404 cites W1998725093 @default.
- W2049066404 cites W2004082676 @default.
- W2049066404 cites W2005687406 @default.
- W2049066404 cites W2006943286 @default.
- W2049066404 cites W2018999493 @default.
- W2049066404 cites W2019668249 @default.
- W2049066404 cites W2021849468 @default.
- W2049066404 cites W2021862805 @default.
- W2049066404 cites W2022030193 @default.
- W2049066404 cites W2033798801 @default.
- W2049066404 cites W2042900801 @default.
- W2049066404 cites W2053577425 @default.
- W2049066404 cites W2054251052 @default.
- W2049066404 cites W2055545493 @default.
- W2049066404 cites W2059272159 @default.
- W2049066404 cites W2071018715 @default.
- W2049066404 cites W2088575697 @default.
- W2049066404 cites W2112916667 @default.
- W2049066404 cites W2116074629 @default.
- W2049066404 cites W2119911133 @default.
- W2049066404 cites W2135470334 @default.
- W2049066404 cites W2138114398 @default.
- W2049066404 cites W2141642647 @default.
- W2049066404 cites W2142777597 @default.
- W2049066404 cites W2143077267 @default.
- W2049066404 cites W2158189659 @default.
- W2049066404 cites W2162877252 @default.
- W2049066404 cites W2165242021 @default.
- W2049066404 cites W2169166924 @default.
- W2049066404 cites W2342344186 @default.
- W2049066404 cites W33811216 @default.
- W2049066404 doi "https://doi.org/10.1378/chest.128.4.2677" @default.
- W2049066404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16236942" @default.
- W2049066404 hasPublicationYear "2005" @default.
- W2049066404 type Work @default.
- W2049066404 sameAs 2049066404 @default.
- W2049066404 citedByCount "126" @default.
- W2049066404 countsByYear W20490664042012 @default.
- W2049066404 countsByYear W20490664042013 @default.
- W2049066404 countsByYear W20490664042014 @default.
- W2049066404 countsByYear W20490664042015 @default.
- W2049066404 countsByYear W20490664042016 @default.
- W2049066404 countsByYear W20490664042017 @default.
- W2049066404 countsByYear W20490664042018 @default.
- W2049066404 countsByYear W20490664042019 @default.
- W2049066404 countsByYear W20490664042020 @default.
- W2049066404 countsByYear W20490664042021 @default.
- W2049066404 countsByYear W20490664042022 @default.
- W2049066404 countsByYear W20490664042023 @default.
- W2049066404 crossrefType "journal-article" @default.
- W2049066404 hasAuthorship W2049066404A5013438849 @default.
- W2049066404 hasAuthorship W2049066404A5015208849 @default.
- W2049066404 hasAuthorship W2049066404A5024108500 @default.
- W2049066404 hasAuthorship W2049066404A5026041374 @default.
- W2049066404 hasAuthorship W2049066404A5030738510 @default.
- W2049066404 hasAuthorship W2049066404A5039836204 @default.
- W2049066404 hasAuthorship W2049066404A5085079099 @default.
- W2049066404 hasConcept C115725540 @default.
- W2049066404 hasConcept C126322002 @default.
- W2049066404 hasConcept C2778384902 @default.
- W2049066404 hasConcept C2778881276 @default.
- W2049066404 hasConcept C2780401358 @default.
- W2049066404 hasConcept C2781090800 @default.
- W2049066404 hasConcept C42219234 @default.
- W2049066404 hasConcept C500558357 @default.
- W2049066404 hasConcept C71924100 @default.
- W2049066404 hasConcept C90924648 @default.
- W2049066404 hasConceptScore W2049066404C115725540 @default.
- W2049066404 hasConceptScore W2049066404C126322002 @default.
- W2049066404 hasConceptScore W2049066404C2778384902 @default.
- W2049066404 hasConceptScore W2049066404C2778881276 @default.
- W2049066404 hasConceptScore W2049066404C2780401358 @default.
- W2049066404 hasConceptScore W2049066404C2781090800 @default.